相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease Role of High-Density Lipoprotein-Proteome Remodeling
Meliana Riwanto et al.
CIRCULATION (2013)
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
Richard Haynes et al.
EUROPEAN HEART JOURNAL (2013)
Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis
Alison M. Strack et al.
JOURNAL OF LIPID RESEARCH (2013)
Niacin and biosynthesis of PGD2 by platelet COX-1 in mice and humans
Wen-Liang Song et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation
Sonia Philipose et al.
PLOS ONE (2012)
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
AMERICAN HEART JOURNAL (2011)
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
Martina Lukasova et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
Christian Besler et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
Mohamad Navab et al.
NATURE REVIEWS CARDIOLOGY (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
Sajoscha A. Sorrentino et al.
CIRCULATION (2010)
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice
Julien Hanson et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease
Dorbie Maccubbin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
Paul M. Ridker
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Allen J. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing
Z Benyó et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
S Tunaru et al.
NATURE MEDICINE (2003)
分享论文
